The Technical Analyst
PLx Pharma Inc [PLXP]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
PLx Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0870
America/New_York / 12 apr 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.53 mill |
| EPS: | -0.390 |
| P/E: | -0.223 |
| Earnings Date: | Aug 10, 2023 |
| SharesOutstanding: | 29.14 mill |
| Avg Daily Volume: | 4.86 mill |
| RATING 2023-05-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.223 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.223 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0213 - 0.0328 ( +/- 469.57%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-03-15 | Giordano Natasha | Buy | 4 100 | Common Stock |
| 2022-03-15 | O'connor Rita M | Buy | 3 700 | Common Stock |
| 2022-03-15 | O'connor Rita M | Buy | 10 000 | Common Stock |
| 2022-02-22 | Valentino Michael J | Buy | 80 000 | Stock Option (right to buy) |
| 2022-02-22 | O'connor Rita M | Buy | 110 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 94 transactions |
| Buy: 5 718 001 | Sell: 1 856 163 |
Forecast:
01:40 - $0
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0870 (0.00% ) |
| Volume | 50.38 mill |
| Avg. Vol. | 4.86 mill |
| % of Avg. Vol | 1 037.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PLXP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PLXP
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
Latest Press Releases
2022-10-26 09:00:00 - Press Release
Plx Pharma Inc. To Report Third Quarter 2022 Financial Results On november 11, 2022, And Provide Business Update
Sparta, n.j., oct. 26, 2022 (globe newswire) -- plx pharma inc. (nasdaq: plxp) (“plx” or the “company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected plxguard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. the company, with its lead products vazalore 81 mg and vazalore 325 mg liquid-filled aspirin capsules (referred to together as “vazalore®”), today announced that it will release its third quarter 2022 financial results before the open of the u.s. financial markets on friday, november 11, 2022.
2022-04-22 06:50:00 - Press Release
Plx Pharma Inc. To Discuss 2022 First Quarter Financial Results On May 13, 2022 Conference Call And Provide Business Update
Sparta, n.j., april 22, 2022 (globe newswire) -- plx pharma inc. (nasdaq: plxp) (“plx” or the “company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected plxguard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. the company, with its lead products vazalore 81 mg and vazalore 325 mg liquid-filled aspirin capsules (referred to together as “vazalore®”), today announced that it will release its 2022 first quarter financial results before the opening of the u.s. financial markets on friday, may 13, 2022...
2022-03-01 06:50:00 - Press Release
Plx Pharma Inc. To Present At Oppenheimer & Co's 32nd Annual Healthcare Conference On March 15, 2022
Sparta, n.j., march 01, 2022 (globe newswire) -- plx pharma inc. (nasdaq: plxp) (“plx” or the “company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected plxguard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. the company, with its lead products vazalore 81 mg and vazalore 325 mg liquid-filled aspirin capsules (referred to together as “vazalore®”), today announced that natasha giordano, president and ceo of plx pharma inc. and rita o'connor, chief financial officer & head of manufacturing & supply chain, will present on march 15, 2022, at oppenheimer & co's 32nd annual healthcare conference, which will be a virtual event this year.
2022-02-22 16:30:00 - Press Release
Plx Pharma Inc. To Discuss 2021 Fourth Quarter Financial Results On March 11, 2022 Conference Call And Provide Business Update
Sparta, n.j., feb. 22, 2022 (globe newswire) -- plx pharma inc. (nasdaq: plxp) (“plx” or the “company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected plxguard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. the company, with its lead products vazalore 81 mg and vazalore 325 mg liquid-filled aspirin capsules (referred to together as “vazalore®”), today announced that it will release its 2021 fourth quarter financial results before the opening of the u.s. financial markets on friday, march 11, 2022...
2021-11-22 09:15:00 - Press Release
Plx Pharma Inc. To Present At Piper Sandler 33rd Annual Healthcare Conference 2021
Sparta, n.j., nov. 22, 2021 (globe newswire) -- plx pharma inc. (nasdaq: plxp) (“plx” or the “company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected plxguard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. the company, with its lead products vazalore™ 325 mg and vazalore™ 81 mg liquid-filled aspirin capsules (referred to together as “vazalore”), announced today that natasha giordano, president and chief executive officer, and rita o'connor, chief financial officer, are scheduled to present virtually at the piper sandler 33rd annual healthcare conference 2021.
Latest News
2023-04-12 08:40:56 - InvestorPlace
Why Is PLx Pharma (PLXP) Stock Down 32% Today?
PLx Pharma (NASDAQ: PLXP ) stock continues to fall on Wednesday as the company gets closer to being delisted from the Nasdaq Exchange . An update from PLx Pharma revealed that the Nasdaq is not giving it another 180-day period to regain compliance with listing rules.
2023-04-11 09:28:19 - InvestorPlace
Why Is PLx Pharma (PLXP) Stock Down 38% Today?
PLx Pharma (NASDAQ: PLXP ) stock is taking a beating on Tuesday and there's a couple of reasons investors will want to know about its fall. First off, traders will keep in mind that PLXP stock underwent a massive rally on Monday.
2023-04-11 06:00:00 - PennyStocks
Spotting Winning Penny Stocks: 3 Top Tips
Can these tips help you make money with penny stocks in 2023? The post Spotting Winning Penny Stocks: 3 Top Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-11-11 11:13:06 - Seeking Alpha
PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript
PLx Pharma Inc. (NASDAQ:PLXP ) Q3 2022 Earnings Conference Call November 11, 2022 8:30 AM ET Company Participants Natasha Giordano - President, Chief Executive Officer Rita O'Connor - Chief Financial Officer Asif Ali - Preventative Cardiologist Janet Barth - Vice President, Investor Relations Conference Call Participants Leland Gershell - Oppenheimer Jason Butler - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to PLx Pharma's third quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode.
2022-11-10 19:33:10 - Zacks Investment Research
PLx Pharma, Inc. (PLXP) Reports Q3 Loss, Misses Revenue Estimates
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 15.91% and 35.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-26 09:00:00 - GlobeNewsWire
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referred to together as “VAZALORE®”), today announced that it will release its third quarter 2022 financial results before the open of the U.S. financial markets on Friday, November 11, 2022.
2022-08-12 13:56:13 - Seeking Alpha
PLx Pharma Inc. (PLXP) CEO, Natasha Giordano on Q2 2022 Results - Earnings Call Transcript
PLx Pharma Inc. (NASDAQ:PLXP ) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Janet Barth - Vice President, Investor Relations & Corporate Communications Natasha Giordano - President & Chief Executive Officer Rita O'Connor - Chief Financial Officer & Head, Manufacturing & Supply Chain Asif Ali - Preventative Cardiologist Conference Call Participants Jason Butler - JMP Securities Leland Gershell - Oppenheimer Elliot Wilbur - Raymond James Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to the PLx Pharma Second Quarter 2022 Earnings Conference Call.
2022-08-12 09:47:10 - Zacks Investment Research
PLx Pharma, Inc. (PLXP) Reports Q2 Loss, Lags Revenue Estimates
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 7.14% and 86.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-05-13 13:25:04 - Seeking Alpha
PLx Pharma (PLXP) CEO, Natasha Giordano on Q1 2022 Results - Earnings Call Transcript
PLx Pharma Inc. (NASDAQ:PLXP ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Natasha Giordano - President, Chief Executive Officer Rita O'Connor - Chief Financial Officer Mike Valentino - Executive Chairman Asif Ali - Preventative Cardiologist Janet Barth - Vice President, Investor Relations Conference Call Participants Leland Gershell - Oppenheimer Elliot Wilbur - Raymond James Jason Butler - JMP Securities Operator Ladies and gentlemen, thank you for standing by and welcome to PLx Pharma's first quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode.
2022-05-13 09:47:13 - Zacks Investment Research
PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?